NCT00309140已完成2 期
An Open-Label Study of Oral Enzastaurin HCl in Patients With Advanced or Metastatic Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs
研究概览
简要总结
This study will collect further basic safety data on participants with cancer treated with enzastaurin. This study is not open to the public.
The purpose of the this study is to extend the clinical experience of participants who complete enzastaurin therapy per clinical pharmacology and biopharmaceutics studies conducted by Eli Lilly and Company and who may benefit from continued enzastaurin therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You must have previously participated in and finished Study H6Q-LC-JCAV (JCAV), Study H6Q-LC-JCAY (JCAY), or other enzastaurin clinical pharmacology and biopharmaceutics studies. If you have had any other cancer treatment (chemotherapy, radiation, anti-cancer hormone therapy), you must have completed it at least 4 weeks ago before you can enroll in this study.
- •You must have a cancer for which no other therapy exists that can prolong your life. This may include participants with treated, stable brain cancer.
- •You must have lesions (areas of cancer in your body) that your doctor can either measure or detect.
- •You either must not be able to become pregnant, (because you've had surgery ["tubes tied" or hysterectomy], you've gone through menopause, or you've had previous radiation for cancer that made you sterile) or your potential to become pregnant must be reduced by the use of an approved birth control method (including intrauterine or barrier devices) during and for 3 to 6 months following the study.
- •You can be either male or female, and must be at least 18 years old.
排除标准
- •You must not have received treatment within the last 30 days with a drug other than enzastaurin that is still experimental (this means it has not received approval to be prescribed, except in a clinical trial).
- •You must not be pregnant or breastfeeding.
- •You must not have central nervous system (CNS) tumors (tumors in your brain and spinal cord). (However, participants who have stable CNS tumors and are taking steroid medication may be included.)
- •You must not have another serious disorder, including active infections that will interfere with your participation in the study.
- •You must not have a second cancer in addition to your primary cancer. Participants with adequately treated skin cancer or who have had another cancer in the past, but have been cancer free for more than 2 years, are eligible.
研究组 & 干预措施
Enzastaurin
Experimental
干预措施: enzastaurin (Drug)
结局指标
主要结局
Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs
时间窗: Baseline through study completion (up to 26 months and 30-day safety follow-up)
Data presented are the number of participants who experienced 1 or more AEs or any serious AEs (SAEs) regardless of causality. A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events section of this report.
次要结局
- Time to Disease Progression (Time to Documented Tumor Activity)(Baseline through study completion (up to 26 months and 30-day safety follow-up))
- Percentage of Participants With Best Overall Response (Documented Antitumor Activity)(Baseline through study completion (up to 26 months and 30-day safety follow-up))
研究者
研究点 (1)
Loading locations...
相似试验
暂停
1 期
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate CancerProstatic NeoplasmNCT01337518Enzon Pharmaceuticals, Inc.150
已完成
2 期
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.Molluscum ContagiosumNCT03186378Verrica Pharmaceuticals Inc.33
已完成
2 期
Arimidex in McCune Albright SyndromeMcCune-Albright SyndromeNCT00055302AstraZeneca40
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ⅡMucopolysaccharidosis IIHunter SyndromeNCT05422482GC Biopharma Corp12
已完成
1 期
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)Cancer of the BreastTriple Negative Breast CancerER+ Breast CancerBreast CancerMetastatic Breast CancerMale Breast CancerAdvanced Breast CancerNCT02580448Innocrin Pharmaceutical175